{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:27:23Z","timestamp":1773890843094,"version":"3.50.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n                           <jats:sup>68<\/jats:sup>Ga-PSMA PET\/CT has become a well-established imaging modality to detect prostate cancer (PCa) metastases in biochemical recurrence. Despite its claimed specificity for PCa, <jats:sup>68<\/jats:sup>Ga-PSMA uptake in tissues unrelated to PCa, particularly in the neovascular tissue of other cancers, has been reported in numerous studies. A 73-year-old man underwent <jats:sup>68<\/jats:sup>Ga-PSMA PET\/CT for biochemical recurrence of PCa 7 years after radical prostatectomy. The <jats:sup>68<\/jats:sup>Ga-PSMA PET\/CT showed 1 lesion with PSMA uptake in the distal left ureter. Histology revealed a low-grade noninvasive papillary urothelial carcinoma. By immunohistochemistry, PSMA expression was observed in the neoplastic urothelial cells and in the vessels of the papillary structures.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002720","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T12:13:13Z","timestamp":1563192793000},"page":"e43-e45","source":"Crossref","is-referenced-by-count":8,"title":["68Ga-PSMA PET\/CT Uptake in the Ureter Caused by Ligand Expression in Urothelial Cancer"],"prefix":"10.1097","volume":"45","author":[{"given":"Helle D.","family":"Zacho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sine H.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Aalborg University Hospital, Aalborg, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Petersen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Aalborg University Hospital, Aalborg, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars J.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"bib1-20230928","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","year":"2017","journal-title":"Eur Urol"},{"key":"bib2-20230928","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","article-title":"(68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","year":"2016","journal-title":"BJU Int"},{"key":"bib3-20230928","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20230928","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","year":"2019","journal-title":"JAMA Oncol"},{"key":"bib5-20230928","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/RLU.0000000000000995","article-title":"Detection of 18F-FDG PET\/CT occult lesions with 18F-DCFPyL PET\/CT in a patient with metastatic renal cell carcinoma","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib6-20230928","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/RLU.0000000000001522","article-title":"Incidental detection of thyroid metastases from renal cell carcinoma using 68Ga-PSMA PET\/CT to assess prostate cancer recurrence","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib7-20230928","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/0972-3919.183615","article-title":"Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy","volume":"31","year":"2016","journal-title":"Indian J Nucl Med"},{"key":"bib8-20230928","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12149-017-1216-x","article-title":"Low levels of PSMA expression limit the utility of (18)F-DCFPyL PET\/CT for imaging urothelial carcinoma","volume":"32","year":"2018","journal-title":"Ann Nucl Med"},{"key":"bib9-20230928","first-page":"4268","article-title":"Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST","volume":"8","year":"2016","journal-title":"Oncotarget"},{"key":"bib10-20230928","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1097\/RLU.0000000000001222","article-title":"Healing sacral fracture masquerading as metastatic bone disease on a 68Ga-PSMA PET\/CT","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib11-20230928","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1097\/RLU.0000000000001340","article-title":"68Ga-PSMA PET\/CT false-positive tracer uptake in Paget disease","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib12-20230928","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/RLU.0000000000001654","article-title":"68Ga-PSMA PET\/CT uptake in intramuscular myxoma imitates prostate cancer metastasis","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib13-20230928","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/RLU.0000000000001308","article-title":"Prostate-specific membrane antigen (PSMA) avid pancreatic neuroendocrine tumor","volume":"41","year":"2016","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T03:45:23Z","timestamp":1695872723000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002720","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,15]]}}}